The Better Care Reconciliation Act is a 142-page bill that largely mirrors the American Health Care Act that passed the House of Representatives last month, with some key differences.
The Food and Drug Administration’s Drug Competition Action Plan begins with a public hearing on July 18 to assess the places where FDA regulations could be creating obstacles to generic access.
The Preserving Patient Access to Compounded Medications Act of 2017 would clarify the Drug Quality and Security Act in a way that would align the statute with congressional intent to balance the issues of public safety and patient access.
The company said that it’s expecting a launch in the second-half of 2017, and that it has already submitted an application to the FDA for a junior version of Symjepi.